Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 19, Issue 8, 2012, Pages 2744-2752

  Hung, Chin Sheng ^a,b   Lin, Shen Fu ^e   Liu, Hui Hsiung ^e   Kuo, Li Jen ^a,b   Li, Li Tzu ^d   Su, Hou Yu ^a,c   Liew, Phui Ly ^f   Lin, Feng Yen ^b,g   Wei, Po Li ^a,b   Liu, Der Zen ^e   Chang, Yu Jia ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Saint Mary's Hospital Luodong   (Taiwan)

^d INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; GEMCITABINE; GLUCOSE REGULATED PROTEIN 78; SMALL INTERFERING RNA; SURVIVIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; LIVER CELL CARCINOMA; NICK END LABELING; OXIDATIVE STRESS; PROTEIN INTERACTION; S PHASE CELL CYCLE CHECKPOINT;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; HUMANS; IN SITU NICK-END LABELING; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84865005511     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2188-z     Document Type: Article

References (43)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin. 58 71 96 18287387 10.3322/CA.2007.0010
2. M Thomas 2009 Molecular targeted therapy for hepatocellular carcinoma J Gastroenterol 44 Suppl 19 136 141 19148808 10.1007/s00535-008-2252-z 1:CAS:528:DC%2BD1MXosVGquw%3D%3D
3. HB El-Serag KL Rudolph 2007 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology. 132 2557 2576 17570226 10.1053/j.gastro.2007.04.061 1:CAS:528:DC%2BD2sXnvFOgsrw%3D
4. D Moradpour HE Blum 2005 Pathogenesis of hepatocellular carcinoma Eur J Gastroenterol Hepatol. 17 477 483 15827436 10.1097/00042737-200505000-00002
5. P Roxburgh TR Evans 2008 Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 25 1089 1104 18972075 10.1007/s12325-008-0113- z 1:CAS:528:DC%2BD1MXktlajtQ%3D%3D
6. RS Finn 2010 Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 16 390 397 20068087 10.1158/1078-0432.CCR-09-2084 1:CAS:528:DC%2BC3cXktF2qsb0%3D
7. V Heinemann W Plunkett 1989 Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3, 4, 5, 6-tetrahydrodeoxyuridine Biochem Pharmacol. 38 4115 4121 2688654 10.1016/0006-2952(89)90693-X 1:CAS:528:DyaK3cXmvFGjug%3D%3D
8. K Ohuchida K Mizumoto T Kayashima, et al. 2011 MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer Ann Surg Oncol. 18 2381 2387 21347785 10.1245/s10434-011-1602- x
9. RJ Bold J Chandra DJ McConkey 1999 Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content Ann Surg Oncol. 6 279 285 10340887 10.1007/s10434-999-0279-x 1:STN:280:DyaK1M3ntVOgtw%3D%3D
10. AN Shah JM Summy J Zhang, et al. 2007 Development and characterization of gemcitabine-resistant pancreatic tumor cells Ann Surg Oncol. 14 3629 3637 17909916 10.1245/s10434-007-9583-5
11. RA Carrasco NB Stamm E Marcusson, et al. 2011 Antisense inhibition of survivin expression as a cancer therapeutic Mol Cancer Ther. 10 221 232 21216939 10.1158/1535-7163.MCT-10-0756 1:CAS:528:DC%2BC3MXhs1yls7k%3D
12. BR Sloat MA Sandoval D Li, et al. 2011 In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int J Pharm. 409 278 288 21371545 10.1016/j.ijpharm.2011.02.037 1:CAS:528:DC%2BC3MXkslektro%3D
13. C Erlichman 1991 Novel chemotherapeutic agents in clinical development Curr Opin Oncol. 3 1037 1042 1688200 10.1097/00001622-199112000-00011 1:STN:280:DyaK3s7itVajug%3D%3D
14. I Graziadei T Kelly M Schirmer, et al. 1998 Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′, 2′- difluorodeoxycytidine on human hepatoma HepG2 cells J Hepatol. 28 504 509 9551690 10.1016/S0168-8278(98)80326-7 1:CAS:528:DyaK1cXmvVWlu7w%3D
15. TS Yang YC Lin JS Chen, et al. 2000 Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma Cancer. 89 750 756 10951336 10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R 1:CAS:528:DC%2BD3cXmtFOnu74%3D
16. D Pastorelli G Cartei F Zustovich, et al. 2006 Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature Ann Oncol 17 Suppl 5 v153 v157 16807446 10.1093/annonc/mdj972
17. G Lombardi F Zustovich F Farinati, et al. 2011 Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study Cancer. 117 125 133 21058409 10.1002/cncr.25578 1:CAS:528:DC%2BC3MXmtl2jug%3D%3D
18. S Louafi V Boige M Ducreux, et al. 2007 Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study Cancer. 109 1384 1390 17330837 10.1002/cncr.22532 1:CAS:528:DC%2BD2sXkslKitbw%3D
19. A Asnacios L Fartoux O Romano, et al. 2008 Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study Cancer. 112 2733 2739 18412149 10.1002/cncr.23489 1:CAS:528:DC%2BD1cXosVGgsr4%3D
20. CS Fuchs JW Clark DP Ryan, et al. 2002 A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma Cancer. 94 3186 3191 12115351 10.1002/cncr.10607 1:CAS:528:DC%2BD38XltlOqurc%3D
21. Z Guan Y Wang S Maoleekoonpairoj, et al. 2003 Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma Br J Cancer. 89 1865 1869 14612894 10.1038/sj.bjc.6601369 1:CAS:528:DC%2BD3sXovVers7s%3D
22. E Mini S Nobili B Caciagli, et al. 2006 Cellular pharmacology of gemcitabine Ann Oncol 17 Suppl 5 v7 v12 16807468 10.1093/annonc/mdj941
23. R Danesi G Altavilla E Giovannetti, et al. 2009 Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors Pharmacogenomics. 10 69 80 19102717 10.2217/14622416.10.1.69 1:CAS:528:DC%2BD1cXhsFCisLbN
24. L Li BL Fridley K Kalari, et al. 2009 Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers PLoS One. 4 e7765 19898621 10.1371/journal.pone.0007765
25. A Wong RA Soo WP Yong, et al. 2009 Clinical pharmacology and pharmacogenetics of gemcitabine Drug Metab Rev. 41 77 88 19514966 10.1080/03602530902741828 1:CAS:528:DC%2BD1MXnsVags74%3D
26. X Song JB Wang DL Yin, et al. 2009 Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma Chin Med J (Engl) 122 2636 2642 1:CAS:528:DC%2BD1MXhsFenu7nJ
27. T Ito K Shiraki K Sugimoto, et al. 2000 Survivin promotes cell proliferation in human hepatocellular carcinoma Hepatology. 31 1080 1085 10796883 10.1053/he.2000.6496 1:CAS:528:DC%2BD3cXjtlyltbg%3D
28. M Ikeguchi T Ueda T Sakatani, et al. 2002 Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma Diagn Mol Pathol. 11 33 40 11854600 10.1097/00019606-200203000-00007
29. Y Sun R Lin J Dai, et al. 2006 Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice Oligonucleotides. 16 365 374 17155911 10.1089/oli.2006.16.365 1:CAS:528:DC%2BD28Xht12gtLfK
30. P Gimenez-Bonafe A Tortosa R Perez-Tomas 2009 Overcoming drug resistance by enhancing apoptosis of tumor cells Curr Cancer Drug Targets. 9 320 340 19442052 10.2174/156800909788166600 1:CAS:528:DC%2BD1MXmslansLs%3D
31. JR Kanwar SK Kamalapuram RK Kanwar 2010 Targeting survivin in cancer: patent review Expert Opin Ther Pat. 20 1723 1737 21083520 10.1517/13543776.2010. 533657 1:CAS:528:DC%2BC3cXhsVekt7fO
32. MT Huang PL Wei JJ Liu, et al. 2010 Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression Ann Surg Oncol. 17 3379 3385 20625840 10.1245/s10434-010-1163-4
33. YJ Chang CJ Tai LJ Kuo, et al. 2011 Glucose-regulated protein 78 (GRP78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma Ann Surg Oncol. 18 2395 2403 21347788 10.1245/s10434-011-1597-3
34. YJ Chang CC Chiu CH Wu, et al. 2010 Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma Ann Surg Oncol. 17 1703 1709 20087778 10.1245/s10434-010-0912-8
35. JF Chiou CJ Tai MT Huang, et al. 2010 Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma Ann Surg Oncol. 17 603 612 19830497 10.1245/s10434-009-0718-8
36. D Dong B Ko P Baumeister, et al. 2005 Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment Cancer Res. 65 5785 5791 15994954 10.1158/0008-5472.CAN-05-0754 1:CAS:528:DC%2BD2MXlslOqsbg%3D
37. SK Wang PH Liang RD Astronomo, et al. 2008 Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN Proc Natl Acad Sci U S A. 105 3690 3695 18310320 10.1073/pnas.0712326105 1:CAS:528:DC%2BD1cXjs1Oit7s%3D
38. S Sowinski C Jolly O Berninghausen, et al. 2008 Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission Nat Cell Biol. 10 211 219 18193035 10.1038/ncb1682 1:CAS:528:DC%2BD1cXhs1Kiuro%3D
39. Wei P-L, Kuo L-J, Wang W, et al. Silencing of glucose-regulated protein 78 (GRP78) enhances cell migration through the upregulation of vimentin in hepatocellular carcinoma cells. Ann Surg Oncol. 2011. doi: 10.1245/s10434-011- 2055-y.
40. J Shen J Liu Y Long, et al. 2009 Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity Acta Biochim Biophys Sin (Shanghai) 41 223 230 10.1093/abbs/gmp005 1:CAS:528:DC%2BD1MXivFeqsLY%3D
41. W Zhang X Chen F Qiu 2003 An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy J Huazhong Univ Sci Technol Med Sci. 23 387 391 15015643 10.1007/BF02829425
42. WP Lee DI Tai SL Tsai, et al. 2003 Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine Cancer Res. 63 6229 6236 14559808 1:CAS:528:DC%2BD3sXotV2juro%3D
43. C-J Tai H Chin-Sheng L-J Kuo, et al. 2012 Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells Ann Surg Oncol. 19 336 343 21516372 10.1245/s10434-011-1692-5